AGM/EGMJun 11, 2026, 04:57 PM
AC Immune AGM Reviews 2025 Financials, Pipeline, and Strategic Outlook
AI Summary
AC Immune SA held its Annual General Meeting on June 11, 2026, reviewing its 2025 financial performance, which included an IFRS net loss of CHF 70.4 million, and outlining key strategic achievements and milestones for 2026. The company reported a strong liquidity position of CHF 91.4 million at year-end 2025, extending its cash runway into Q4 2027, and provided a 2026 cash burn guidance of CHF 55-65 million. Shareholders will vote on various proposals, including the approval of financial statements, compensation for the Board and Executive Management, and changes to the Articles of Association regarding capital structure.
Key Highlights
- AC Immune reported an IFRS net loss of CHF 70.4 million for the year ended December 31, 2025.
- Total liquidity stood at CHF 91.4 million as of December 31, 2025, extending the cash runway into Q4 2027.
- The company projects an annual cash burn of CHF 55-65 million for 2026.
- Key pipeline milestones for H2 2026 include ACI-24 ABATE Phase 2 trial readouts and completion of NLRP3 inhibitor Phase 1 trial.
- Shareholders will vote on approving 2025 financial statements and an advisory vote on the 2025 Compensation Report.
- Proposals include maximum aggregate compensation of CHF 1,029,000 for the Board (2026-2027) and CHF 6,742,000 for Executive Management (2027).
- The Board proposes introducing a capital band and increasing conditional share capital for employee benefit plans to CHF 150,000.00.
Price Impact
More from ACIU